Baseline characteristics of patients from the pooled STEP-HFpEF and STEP-HFpEF-DM trials, stratified by baseline diuretic use
| Baseline characteristicsa . | Diuretic group . | P-value . | ||||
|---|---|---|---|---|---|---|
| No diuretic (n = 220) . | Non-loop diuretic only (n = 223) . | Loop diuretic, dose < 40 mg/day (n = 219) . | Loop diuretic, dose = 40 mg/day (n = 309) . | Loop diuretic, dose > 40 mg/day (n = 174) . | ||
| Female sex, n (%) | 114 (51.8) | 108 (48.4) | 120 (54.8) | 157 (50.8) | 71 (40.8) | .14 |
| Age, years, n (%) | .061 | |||||
| <65 | 88 (40.0) | 69 (30.9) | 65 (29.7) | 97 (31.4) | 49 (28.2) | |
| 65–79 | 116 (52.7) | 140 (62.8) | 131 (59.8) | 174 (56.3) | 105 (60.3) | |
| ≥80 | 16 (7.3) | 14 (6.3) | 23 (10.5) | 38 (12.3) | 20 (11.5) | |
| Race,bn (%) | <.001 | |||||
| Asian | 38 (17.3) | 14 (6.3) | 15 (6.8) | 8 (2.6) | 1 (0.6) | |
| Black or African American | 6 (2.7) | 12 (5.4) | 4 (1.8) | 14 (4.5) | 3 (1.7) | |
| Other | 0 (0.0) | 1 (0.4) | 3 (1.4) | 0 (0.0) | 0 (0.0) | |
| White | 176 (80.0) | 196 (87.9) | 197 (90.0) | 287 (92.9) | 170 (97.7) | |
| Body weight, kg | 99.2 (90.4, 112.7) | 101.3 (89.5, 115.5) | 100.5 (87.4, 116.0) | 106.2 (96.0, 125.1) | 110.4 (97.2, 122.9) | <.001 |
| BMI, kg/m2 | 37.2 (34.1, 41.3) | 37.3 (34.3, 40.6) | 36.9 (33.6, 41.3) | 39.3 (35.4, 43.7) | 39.2 (35.3, 44.9) | <.001 |
| Waist circumference, cm | 117.0 (108.3, 126.0) | 118.4 (111.0, 127.1) | 118.0 (108.5, 126.0) | 122.0 (114.0, 132.0) | 124.8 (114.7, 134.6) | <.001 |
| Systolic BP, mmHg | 133.0 (123.0, 145.0) | 137.0 (127.0, 146.0) | 134.0 (122.0, 141.0) | 133.0 (124.0, 144.0) | 130.0 (120.0, 144.0) | .010 |
| NYHA class, n (%) | <.001 | |||||
| II | 171 (77.7) | 170 (76.2) | 149 (68.0) | 197 (63.8) | 98 (56.3) | |
| III | 49 (22.3) | 53 (23.8) | 70 (32.0) | 110 (35.6) | 76 (43.7) | |
| IV | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.6) | 0 (0.0) | |
| LVEF, % | 60.0 (55.0, 61.0) | 57.0 (50.0, 60.0) | 55.0 (50.0, 60.0) | 56.0 (51.0, 60.0) | 55.0 (50.0, 61.0) | <.001 |
| KCCQ-CSS, score | 65.1 (50.5, 77.1) | 65.4 (49.5, 77.1) | 57.3 (44.3, 69.8) | 55.7 (39.6, 68.2) | 50.0 (35.4, 66.7) | <.001 |
| 6MWD, metres | 336.3 (249.3, 399.8) | 338.8 (261.5, 382.0) | 288.9 (220.0, 362.0) | 265.0 (202.0, 340.0) | 260.6 (192.0, 340.0) | <.001 |
| CRP, mg/L | 3.4 (1.6, 8.0) | 2.7 (1.6, 5.9) | 3.2 (1.7, 6.5) | 4.7 (2.2, 9.7) | 4.2 (2.1, 9.5) | <.001 |
| NT-proBNP, pg/mL | 338.3 (207.2, 849.1) | 392.4 (208.9, 807.6) | 463.4 (258.8, 981.9) | 500.7 (244.8, 1091.0) | 785.7 (303.6, 1407.2) | <.001 |
| Comorbidities at screening, n (%) | ||||||
| Hypertension | 153 (69.5) | 201 (90.1) | 192 (87.7) | 262 (84.8) | 151 (86.8) | <.001 |
| Atrial fibrillation | 74 (33.6) | 89 (39.9) | 101 (46.1) | 155 (50.2) | 99 (56.9) | <.001 |
| Obstructive sleep apnoea | 17 (7.7) | 26 (11.7) | 19 (8.7) | 32 (10.4) | 25 (14.4) | .11 |
| Coronary artery disease | 98 (44.5) | 89 (39.9) | 95 (43.4) | 99 (32.0) | 72 (41.4) | .077 |
| Diabetes | 118 (53.6) | 125 (56.1) | 124 (56.6) | 158 (51.1) | 91 (52.3) | .44 |
| Concomitant medications, n (%) | ||||||
| Beta blockers | 164 (74.5) | 187 (83.9) | 182 (83.1) | 251 (81.2) | 144 (82.8) | .11 |
| SGLT2 inhibitors | 35 (15.9) | 44 (19.7) | 52 (23.7) | 52 (16.8) | 38 (21.8) | .40 |
| MRAs | 0 (0.0) | 89 (39.9) | 85 (38.8) | 119 (38.5) | 91 (52.3) | <.001 |
| Thiazide diuretics | 0 (0.0) | 102 (45.7) | 23 (10.5) | 31 (10) | 19 (10.9) | .052 |
| ACEi/ARB (ARNi) | 149 (67.7) | 194 (87.0) | 180 (82.2) | 246 (79.6) | 130 (74.7) | .32 |
| ARNi | 4 (1.8) | 13 (5.8) | 18 (8.2) | 13 (4.2) | 10 (5.7) | .22 |
| Insulin and analogues | 19 (8.6) | 20 (9.0) | 24 (11.0) | 37 (12.0) | 28 (16.1) | .013 |
| Sulfonylureas | 19 (8.6) | 26 (11.7) | 29 (13.2) | 19 (6.1) | 15 (8.6) | .35 |
| DPP-4 inhibitors | 27 (12.3) | 19 (8.5) | 16 (7.3) | 19 (6.1) | 11 (6.3) | .011 |
| Baseline characteristicsa . | Diuretic group . | P-value . | ||||
|---|---|---|---|---|---|---|
| No diuretic (n = 220) . | Non-loop diuretic only (n = 223) . | Loop diuretic, dose < 40 mg/day (n = 219) . | Loop diuretic, dose = 40 mg/day (n = 309) . | Loop diuretic, dose > 40 mg/day (n = 174) . | ||
| Female sex, n (%) | 114 (51.8) | 108 (48.4) | 120 (54.8) | 157 (50.8) | 71 (40.8) | .14 |
| Age, years, n (%) | .061 | |||||
| <65 | 88 (40.0) | 69 (30.9) | 65 (29.7) | 97 (31.4) | 49 (28.2) | |
| 65–79 | 116 (52.7) | 140 (62.8) | 131 (59.8) | 174 (56.3) | 105 (60.3) | |
| ≥80 | 16 (7.3) | 14 (6.3) | 23 (10.5) | 38 (12.3) | 20 (11.5) | |
| Race,bn (%) | <.001 | |||||
| Asian | 38 (17.3) | 14 (6.3) | 15 (6.8) | 8 (2.6) | 1 (0.6) | |
| Black or African American | 6 (2.7) | 12 (5.4) | 4 (1.8) | 14 (4.5) | 3 (1.7) | |
| Other | 0 (0.0) | 1 (0.4) | 3 (1.4) | 0 (0.0) | 0 (0.0) | |
| White | 176 (80.0) | 196 (87.9) | 197 (90.0) | 287 (92.9) | 170 (97.7) | |
| Body weight, kg | 99.2 (90.4, 112.7) | 101.3 (89.5, 115.5) | 100.5 (87.4, 116.0) | 106.2 (96.0, 125.1) | 110.4 (97.2, 122.9) | <.001 |
| BMI, kg/m2 | 37.2 (34.1, 41.3) | 37.3 (34.3, 40.6) | 36.9 (33.6, 41.3) | 39.3 (35.4, 43.7) | 39.2 (35.3, 44.9) | <.001 |
| Waist circumference, cm | 117.0 (108.3, 126.0) | 118.4 (111.0, 127.1) | 118.0 (108.5, 126.0) | 122.0 (114.0, 132.0) | 124.8 (114.7, 134.6) | <.001 |
| Systolic BP, mmHg | 133.0 (123.0, 145.0) | 137.0 (127.0, 146.0) | 134.0 (122.0, 141.0) | 133.0 (124.0, 144.0) | 130.0 (120.0, 144.0) | .010 |
| NYHA class, n (%) | <.001 | |||||
| II | 171 (77.7) | 170 (76.2) | 149 (68.0) | 197 (63.8) | 98 (56.3) | |
| III | 49 (22.3) | 53 (23.8) | 70 (32.0) | 110 (35.6) | 76 (43.7) | |
| IV | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.6) | 0 (0.0) | |
| LVEF, % | 60.0 (55.0, 61.0) | 57.0 (50.0, 60.0) | 55.0 (50.0, 60.0) | 56.0 (51.0, 60.0) | 55.0 (50.0, 61.0) | <.001 |
| KCCQ-CSS, score | 65.1 (50.5, 77.1) | 65.4 (49.5, 77.1) | 57.3 (44.3, 69.8) | 55.7 (39.6, 68.2) | 50.0 (35.4, 66.7) | <.001 |
| 6MWD, metres | 336.3 (249.3, 399.8) | 338.8 (261.5, 382.0) | 288.9 (220.0, 362.0) | 265.0 (202.0, 340.0) | 260.6 (192.0, 340.0) | <.001 |
| CRP, mg/L | 3.4 (1.6, 8.0) | 2.7 (1.6, 5.9) | 3.2 (1.7, 6.5) | 4.7 (2.2, 9.7) | 4.2 (2.1, 9.5) | <.001 |
| NT-proBNP, pg/mL | 338.3 (207.2, 849.1) | 392.4 (208.9, 807.6) | 463.4 (258.8, 981.9) | 500.7 (244.8, 1091.0) | 785.7 (303.6, 1407.2) | <.001 |
| Comorbidities at screening, n (%) | ||||||
| Hypertension | 153 (69.5) | 201 (90.1) | 192 (87.7) | 262 (84.8) | 151 (86.8) | <.001 |
| Atrial fibrillation | 74 (33.6) | 89 (39.9) | 101 (46.1) | 155 (50.2) | 99 (56.9) | <.001 |
| Obstructive sleep apnoea | 17 (7.7) | 26 (11.7) | 19 (8.7) | 32 (10.4) | 25 (14.4) | .11 |
| Coronary artery disease | 98 (44.5) | 89 (39.9) | 95 (43.4) | 99 (32.0) | 72 (41.4) | .077 |
| Diabetes | 118 (53.6) | 125 (56.1) | 124 (56.6) | 158 (51.1) | 91 (52.3) | .44 |
| Concomitant medications, n (%) | ||||||
| Beta blockers | 164 (74.5) | 187 (83.9) | 182 (83.1) | 251 (81.2) | 144 (82.8) | .11 |
| SGLT2 inhibitors | 35 (15.9) | 44 (19.7) | 52 (23.7) | 52 (16.8) | 38 (21.8) | .40 |
| MRAs | 0 (0.0) | 89 (39.9) | 85 (38.8) | 119 (38.5) | 91 (52.3) | <.001 |
| Thiazide diuretics | 0 (0.0) | 102 (45.7) | 23 (10.5) | 31 (10) | 19 (10.9) | .052 |
| ACEi/ARB (ARNi) | 149 (67.7) | 194 (87.0) | 180 (82.2) | 246 (79.6) | 130 (74.7) | .32 |
| ARNi | 4 (1.8) | 13 (5.8) | 18 (8.2) | 13 (4.2) | 10 (5.7) | .22 |
| Insulin and analogues | 19 (8.6) | 20 (9.0) | 24 (11.0) | 37 (12.0) | 28 (16.1) | .013 |
| Sulfonylureas | 19 (8.6) | 26 (11.7) | 29 (13.2) | 19 (6.1) | 15 (8.6) | .35 |
| DPP-4 inhibitors | 27 (12.3) | 19 (8.5) | 16 (7.3) | 19 (6.1) | 11 (6.3) | .011 |
Percentages may not equal 100% due to rounding. Data are median (Q1, Q3) unless otherwise stated and are from the full analysis set. P-values for continuous variables computed using the Jonckheere–Terpstra trend test for continuous variables, the Cochran–Armitage trend test for binary variables, and the Cochran–Mantel–Haenszel test for multinomial variables.
6MWD, 6 min walking distance; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; CRP, high-sensitivity C-reactive protein; DM, diabetes mellitus; DPP-4, dipeptidyl peptidase-4; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire clinical summary score; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; Q, quartile; SGLT2, sodium–glucose cotransporter 2.
aA total of 1146 participants were randomized; however, one participant was randomized in error such that the full analysis set comprises 1145 participants.
bRace was reported by the investigator.
Baseline characteristics of patients from the pooled STEP-HFpEF and STEP-HFpEF-DM trials, stratified by baseline diuretic use
| Baseline characteristicsa . | Diuretic group . | P-value . | ||||
|---|---|---|---|---|---|---|
| No diuretic (n = 220) . | Non-loop diuretic only (n = 223) . | Loop diuretic, dose < 40 mg/day (n = 219) . | Loop diuretic, dose = 40 mg/day (n = 309) . | Loop diuretic, dose > 40 mg/day (n = 174) . | ||
| Female sex, n (%) | 114 (51.8) | 108 (48.4) | 120 (54.8) | 157 (50.8) | 71 (40.8) | .14 |
| Age, years, n (%) | .061 | |||||
| <65 | 88 (40.0) | 69 (30.9) | 65 (29.7) | 97 (31.4) | 49 (28.2) | |
| 65–79 | 116 (52.7) | 140 (62.8) | 131 (59.8) | 174 (56.3) | 105 (60.3) | |
| ≥80 | 16 (7.3) | 14 (6.3) | 23 (10.5) | 38 (12.3) | 20 (11.5) | |
| Race,bn (%) | <.001 | |||||
| Asian | 38 (17.3) | 14 (6.3) | 15 (6.8) | 8 (2.6) | 1 (0.6) | |
| Black or African American | 6 (2.7) | 12 (5.4) | 4 (1.8) | 14 (4.5) | 3 (1.7) | |
| Other | 0 (0.0) | 1 (0.4) | 3 (1.4) | 0 (0.0) | 0 (0.0) | |
| White | 176 (80.0) | 196 (87.9) | 197 (90.0) | 287 (92.9) | 170 (97.7) | |
| Body weight, kg | 99.2 (90.4, 112.7) | 101.3 (89.5, 115.5) | 100.5 (87.4, 116.0) | 106.2 (96.0, 125.1) | 110.4 (97.2, 122.9) | <.001 |
| BMI, kg/m2 | 37.2 (34.1, 41.3) | 37.3 (34.3, 40.6) | 36.9 (33.6, 41.3) | 39.3 (35.4, 43.7) | 39.2 (35.3, 44.9) | <.001 |
| Waist circumference, cm | 117.0 (108.3, 126.0) | 118.4 (111.0, 127.1) | 118.0 (108.5, 126.0) | 122.0 (114.0, 132.0) | 124.8 (114.7, 134.6) | <.001 |
| Systolic BP, mmHg | 133.0 (123.0, 145.0) | 137.0 (127.0, 146.0) | 134.0 (122.0, 141.0) | 133.0 (124.0, 144.0) | 130.0 (120.0, 144.0) | .010 |
| NYHA class, n (%) | <.001 | |||||
| II | 171 (77.7) | 170 (76.2) | 149 (68.0) | 197 (63.8) | 98 (56.3) | |
| III | 49 (22.3) | 53 (23.8) | 70 (32.0) | 110 (35.6) | 76 (43.7) | |
| IV | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.6) | 0 (0.0) | |
| LVEF, % | 60.0 (55.0, 61.0) | 57.0 (50.0, 60.0) | 55.0 (50.0, 60.0) | 56.0 (51.0, 60.0) | 55.0 (50.0, 61.0) | <.001 |
| KCCQ-CSS, score | 65.1 (50.5, 77.1) | 65.4 (49.5, 77.1) | 57.3 (44.3, 69.8) | 55.7 (39.6, 68.2) | 50.0 (35.4, 66.7) | <.001 |
| 6MWD, metres | 336.3 (249.3, 399.8) | 338.8 (261.5, 382.0) | 288.9 (220.0, 362.0) | 265.0 (202.0, 340.0) | 260.6 (192.0, 340.0) | <.001 |
| CRP, mg/L | 3.4 (1.6, 8.0) | 2.7 (1.6, 5.9) | 3.2 (1.7, 6.5) | 4.7 (2.2, 9.7) | 4.2 (2.1, 9.5) | <.001 |
| NT-proBNP, pg/mL | 338.3 (207.2, 849.1) | 392.4 (208.9, 807.6) | 463.4 (258.8, 981.9) | 500.7 (244.8, 1091.0) | 785.7 (303.6, 1407.2) | <.001 |
| Comorbidities at screening, n (%) | ||||||
| Hypertension | 153 (69.5) | 201 (90.1) | 192 (87.7) | 262 (84.8) | 151 (86.8) | <.001 |
| Atrial fibrillation | 74 (33.6) | 89 (39.9) | 101 (46.1) | 155 (50.2) | 99 (56.9) | <.001 |
| Obstructive sleep apnoea | 17 (7.7) | 26 (11.7) | 19 (8.7) | 32 (10.4) | 25 (14.4) | .11 |
| Coronary artery disease | 98 (44.5) | 89 (39.9) | 95 (43.4) | 99 (32.0) | 72 (41.4) | .077 |
| Diabetes | 118 (53.6) | 125 (56.1) | 124 (56.6) | 158 (51.1) | 91 (52.3) | .44 |
| Concomitant medications, n (%) | ||||||
| Beta blockers | 164 (74.5) | 187 (83.9) | 182 (83.1) | 251 (81.2) | 144 (82.8) | .11 |
| SGLT2 inhibitors | 35 (15.9) | 44 (19.7) | 52 (23.7) | 52 (16.8) | 38 (21.8) | .40 |
| MRAs | 0 (0.0) | 89 (39.9) | 85 (38.8) | 119 (38.5) | 91 (52.3) | <.001 |
| Thiazide diuretics | 0 (0.0) | 102 (45.7) | 23 (10.5) | 31 (10) | 19 (10.9) | .052 |
| ACEi/ARB (ARNi) | 149 (67.7) | 194 (87.0) | 180 (82.2) | 246 (79.6) | 130 (74.7) | .32 |
| ARNi | 4 (1.8) | 13 (5.8) | 18 (8.2) | 13 (4.2) | 10 (5.7) | .22 |
| Insulin and analogues | 19 (8.6) | 20 (9.0) | 24 (11.0) | 37 (12.0) | 28 (16.1) | .013 |
| Sulfonylureas | 19 (8.6) | 26 (11.7) | 29 (13.2) | 19 (6.1) | 15 (8.6) | .35 |
| DPP-4 inhibitors | 27 (12.3) | 19 (8.5) | 16 (7.3) | 19 (6.1) | 11 (6.3) | .011 |
| Baseline characteristicsa . | Diuretic group . | P-value . | ||||
|---|---|---|---|---|---|---|
| No diuretic (n = 220) . | Non-loop diuretic only (n = 223) . | Loop diuretic, dose < 40 mg/day (n = 219) . | Loop diuretic, dose = 40 mg/day (n = 309) . | Loop diuretic, dose > 40 mg/day (n = 174) . | ||
| Female sex, n (%) | 114 (51.8) | 108 (48.4) | 120 (54.8) | 157 (50.8) | 71 (40.8) | .14 |
| Age, years, n (%) | .061 | |||||
| <65 | 88 (40.0) | 69 (30.9) | 65 (29.7) | 97 (31.4) | 49 (28.2) | |
| 65–79 | 116 (52.7) | 140 (62.8) | 131 (59.8) | 174 (56.3) | 105 (60.3) | |
| ≥80 | 16 (7.3) | 14 (6.3) | 23 (10.5) | 38 (12.3) | 20 (11.5) | |
| Race,bn (%) | <.001 | |||||
| Asian | 38 (17.3) | 14 (6.3) | 15 (6.8) | 8 (2.6) | 1 (0.6) | |
| Black or African American | 6 (2.7) | 12 (5.4) | 4 (1.8) | 14 (4.5) | 3 (1.7) | |
| Other | 0 (0.0) | 1 (0.4) | 3 (1.4) | 0 (0.0) | 0 (0.0) | |
| White | 176 (80.0) | 196 (87.9) | 197 (90.0) | 287 (92.9) | 170 (97.7) | |
| Body weight, kg | 99.2 (90.4, 112.7) | 101.3 (89.5, 115.5) | 100.5 (87.4, 116.0) | 106.2 (96.0, 125.1) | 110.4 (97.2, 122.9) | <.001 |
| BMI, kg/m2 | 37.2 (34.1, 41.3) | 37.3 (34.3, 40.6) | 36.9 (33.6, 41.3) | 39.3 (35.4, 43.7) | 39.2 (35.3, 44.9) | <.001 |
| Waist circumference, cm | 117.0 (108.3, 126.0) | 118.4 (111.0, 127.1) | 118.0 (108.5, 126.0) | 122.0 (114.0, 132.0) | 124.8 (114.7, 134.6) | <.001 |
| Systolic BP, mmHg | 133.0 (123.0, 145.0) | 137.0 (127.0, 146.0) | 134.0 (122.0, 141.0) | 133.0 (124.0, 144.0) | 130.0 (120.0, 144.0) | .010 |
| NYHA class, n (%) | <.001 | |||||
| II | 171 (77.7) | 170 (76.2) | 149 (68.0) | 197 (63.8) | 98 (56.3) | |
| III | 49 (22.3) | 53 (23.8) | 70 (32.0) | 110 (35.6) | 76 (43.7) | |
| IV | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.6) | 0 (0.0) | |
| LVEF, % | 60.0 (55.0, 61.0) | 57.0 (50.0, 60.0) | 55.0 (50.0, 60.0) | 56.0 (51.0, 60.0) | 55.0 (50.0, 61.0) | <.001 |
| KCCQ-CSS, score | 65.1 (50.5, 77.1) | 65.4 (49.5, 77.1) | 57.3 (44.3, 69.8) | 55.7 (39.6, 68.2) | 50.0 (35.4, 66.7) | <.001 |
| 6MWD, metres | 336.3 (249.3, 399.8) | 338.8 (261.5, 382.0) | 288.9 (220.0, 362.0) | 265.0 (202.0, 340.0) | 260.6 (192.0, 340.0) | <.001 |
| CRP, mg/L | 3.4 (1.6, 8.0) | 2.7 (1.6, 5.9) | 3.2 (1.7, 6.5) | 4.7 (2.2, 9.7) | 4.2 (2.1, 9.5) | <.001 |
| NT-proBNP, pg/mL | 338.3 (207.2, 849.1) | 392.4 (208.9, 807.6) | 463.4 (258.8, 981.9) | 500.7 (244.8, 1091.0) | 785.7 (303.6, 1407.2) | <.001 |
| Comorbidities at screening, n (%) | ||||||
| Hypertension | 153 (69.5) | 201 (90.1) | 192 (87.7) | 262 (84.8) | 151 (86.8) | <.001 |
| Atrial fibrillation | 74 (33.6) | 89 (39.9) | 101 (46.1) | 155 (50.2) | 99 (56.9) | <.001 |
| Obstructive sleep apnoea | 17 (7.7) | 26 (11.7) | 19 (8.7) | 32 (10.4) | 25 (14.4) | .11 |
| Coronary artery disease | 98 (44.5) | 89 (39.9) | 95 (43.4) | 99 (32.0) | 72 (41.4) | .077 |
| Diabetes | 118 (53.6) | 125 (56.1) | 124 (56.6) | 158 (51.1) | 91 (52.3) | .44 |
| Concomitant medications, n (%) | ||||||
| Beta blockers | 164 (74.5) | 187 (83.9) | 182 (83.1) | 251 (81.2) | 144 (82.8) | .11 |
| SGLT2 inhibitors | 35 (15.9) | 44 (19.7) | 52 (23.7) | 52 (16.8) | 38 (21.8) | .40 |
| MRAs | 0 (0.0) | 89 (39.9) | 85 (38.8) | 119 (38.5) | 91 (52.3) | <.001 |
| Thiazide diuretics | 0 (0.0) | 102 (45.7) | 23 (10.5) | 31 (10) | 19 (10.9) | .052 |
| ACEi/ARB (ARNi) | 149 (67.7) | 194 (87.0) | 180 (82.2) | 246 (79.6) | 130 (74.7) | .32 |
| ARNi | 4 (1.8) | 13 (5.8) | 18 (8.2) | 13 (4.2) | 10 (5.7) | .22 |
| Insulin and analogues | 19 (8.6) | 20 (9.0) | 24 (11.0) | 37 (12.0) | 28 (16.1) | .013 |
| Sulfonylureas | 19 (8.6) | 26 (11.7) | 29 (13.2) | 19 (6.1) | 15 (8.6) | .35 |
| DPP-4 inhibitors | 27 (12.3) | 19 (8.5) | 16 (7.3) | 19 (6.1) | 11 (6.3) | .011 |
Percentages may not equal 100% due to rounding. Data are median (Q1, Q3) unless otherwise stated and are from the full analysis set. P-values for continuous variables computed using the Jonckheere–Terpstra trend test for continuous variables, the Cochran–Armitage trend test for binary variables, and the Cochran–Mantel–Haenszel test for multinomial variables.
6MWD, 6 min walking distance; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; CRP, high-sensitivity C-reactive protein; DM, diabetes mellitus; DPP-4, dipeptidyl peptidase-4; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire clinical summary score; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; Q, quartile; SGLT2, sodium–glucose cotransporter 2.
aA total of 1146 participants were randomized; however, one participant was randomized in error such that the full analysis set comprises 1145 participants.
bRace was reported by the investigator.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
